对血多原子数据跨祖先的分析发现了与阿尔茨海默病相关的新途径
Chengran Yang1,2, Jigyasha Timsina1,2, Menghan Liu1,2
1Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|February 7, 2026
概括
这项研究整合了多祖先的数据,以确定阿尔茨海默病 (AD) 风险因素. 发现了新的蛋白质和代谢物,突出显示了欧洲和非洲祖先对AD的共同和独特途径.
科学领域:
- 遗传学 遗传学 是一个
- 神经科学是一个神经科学.
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 遗传研究往往缺乏多祖先和多原子数据集成.
- 识别祖先特定的AD风险因子对于个性化医学至关重要.
研究的目的:
- 在欧洲 (EUR) 和非洲 (AFR) 祖先之间进行分子表型 (蛋白质组,代谢组) 和AD风险之间的遗传同地化.
- 在不同的人群中识别共同和独特的AD风险因子和生物途径.
主要方法:
- 在EUR/AFR蛋白质学/代谢学数据和大型EURAD全基因组关联研究之间进行遗传局部化分析.
- 路径丰富分析以确定AD风险背后的生物机制.
主要成果:
- 21种蛋白质和1种代谢物显示在EUR和AFR祖先中具有AD风险的共享局部化.
- 观察到重要的祖先特异性发现:25%的AFR和60%的EUR蛋白质;50%的AFR和10%的EUR代谢物是独一无二的.
- 介素-1 生产和脂质通路被提名为分别为蛋白质组和代谢组发现的共同潜在机制.
结论:
- 血蛋白质组学和代谢组学数据集可以精确地确定不同人群中的AD风险因子.
- 很大一部分发现是新发现,特别是在非洲祖先的蛋白质组学和欧洲祖先的代谢组学中.
- 在使用非洲特异性全基因组关联研究数据对非洲参与者的研究结果进行进一步验证是有必要的.
更多相关视频
09:47DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
Published on: December 15, 2023
08:51Application of Unsupervised Multi-Omic Factor Analysis to Uncover Patterns of Variation and Molecular Processes Linked to Cardiovascular Disease
Published on: September 20, 2024
相关概念视频
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...